Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Pediatr Blood Cancer. 2014 Oct 12;62(5):743–750. doi: 10.1002/pbc.25269

Table II.

Non-Dose Limiting Hematologic Toxicities Observed in Evaluable Patients

Part A NTX-010 dose level 1 (1×109 vp/kg; n=6)
Toxicity Type Maximum grade of toxicity across cycle
1 (Total, 6 cycles)
Maximum grade of toxicity across post
documented viral clearance cycles
(Total, 4 cycles)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Anemia 1 2
Lymphocyte count decreased 2
Neutrophil count decreased 2 1 1 1
Platelet count decreased 2 1
White blood cell decreased 3 1
Part A NTX-010 dose level 2 (1×1010 vp/kg; n=3)
Toxicity Type Maximum grade of toxicity across
cycle 1 (Total, 3 cycles)
Maximum grade of toxicity across post
documented viral clearance cycles
(Total, 5 cycles)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Anemia 1 1
Lymphocyte count decreased 1 1 2
Neutrophil count decreased 1 1
Platelet count decreased 3 1
White blood cell decreased 1 2
Part A NTX-010 dose level 3 (1×1011vp/kg; n=3)
Toxicity Type Maximum grade of toxicity across
cycle 1 (Total, 3 cycles)
Maximum grade of toxicity across post
documented viral clearance cycles
(Total, 3 cycles)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Anemia 1 1
Lymphocyte count decreased 2 1
Neutrophil count decreased 1 1
Platelet count decreased 1 1
White blood cell decreased 2 1
Part B NTX-010 dose level 1 (1×1011vp/kg plus cyclophosphamide; n=6)
Toxicity Type Maximum grade of toxicity across
cycle 1 (Total, 6 cycles)
Maximum grade of toxicity across post
documented viral clearance cycles
(Total, 4 cycles)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Anemia 2 2
Lymphocyte count decreased 2 2 2
Neutrophil count decreased 1 4
Platelet count decreased 1 2 1
White blood cell decreased 2 3